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PCV25 SMOKING AND STROKE IN THE CHINESE SMOKING POPULATION
Wang L g 1 , Li Y 2 1 Sichuan University, Chengdu, Sichuan, China, 2 West China Hospital, Sichuan University, Chengdu, China OBJECTIVES: Worldwide, the association of passive smoking with development of stroke has been ascertained. However, it remains unknown of the magnitude of the association in the Chinese population. We thus systematically reviewed the published studies worldwide. METHODS: We searched Medline, EMBASE, and three other Chinese databases from their inception to June, 2008 . We included case-control and cohort studies that investigated the association of smoking with stroke, and that provided data on the magnitude of the association. Two reviewers screened the eligibility, assessed the extent of the bias, and extracted data independently. We obtained the unadjusted and adjusted estimates of studies. We pooled the trial data using the random-effect model and explored the heterogeneity by the pre-specifi ed variables. RESULTS: We included 49 studies (n 58,872), 8 of which were cohort studies (n 42,755) and 41 case-control studies (cumulative cases 7 883, controls 9 590). Smoking increased the risk of stroke by 75% (OR 1.75, 95%CI 1.51 to 2.03). Pooling of adjusted estimates of 31 studies (n 26,028) showed the risk of stroke was increased by 81% in smokers (1.81, 1.57 to 2.08). The magnitude of the association was not statistically different in different type of strokes: hemorrhagic stroke 1.65 (1.29 to 2.11) and ischemic stroke 1.79 (1.20 to 2.68). No dose-response relationship was found between amount of smoking and the risk of stroke. CONCLUSIONS: The increased risk of stroke associated with smoking in the Chinese population has been ascertained. To analyze the health care utilization and risk profi les of patients with metabolic syndrome (MS) based on subgroups identifi ed by a latent class analysis. METHODS: Utilizing the medical record database from GE Healthcare, we estimate a set of regressions to take a closer look at the effect of metabolic syndrome (MS) on patients' hospital admission, offi ce visit, and the risk of developing one particular type of cardiovascular disease, coronary heart disease (CHD). Patients are identifi ed as having MS by using the guidelines proposed by the National Cholesterol Education Program Adult Treatment Panel III. We conduct the analysis in this study in the following steps; fi rst, we adopt negative binominal regression models to estimate the effect of MS on hospital admission and offi ce visit; second, Probit models are applied to examine the relationship between MS and CHD; and third, the results from the Latent Class Analysis, which identifi es fi ve subgroups of MS patients by risk factors, are integrated into the regression estimations. RESULTS: We fi nd 1) that patients with MS have higher number of hospital admissions and offi ce visits, and are more likely to develop CHD than those without MS, and 2) that MS patients with abnormal blood pressure are more likely to be hospitalized than MS patients with normal blood pressure. Strikingly, we fi nd, by integrating the results from a latent class analysis, that MS patients with the simultaneous presence of three risk factors, abnormal HDL, waist circumference, and blood pressure, are more likely to develop CHD than other types of MS patients. CONCLUSIONS: LCA offers a useful method to help better classify MS patients into sub groups by shared group-specifi c characteristics that would be hard to measure otherwise. Based on the LCA study, we confi rm that MS patients with multiple risk factors are more likely to develop CHD conditions. Atrial fi brillation (AF) poses a substantial health burden. While analyses of the AFFIRM study showed that maintenance of sinus rhythm (SR) reduced the risk of stroke and death, due to their toxicity, antiarrhythmic drug (AAD) use was found to be independently associated with increased mortality. OBJECTIVES: To estimate the benefi ts of SR maintenance, in order to understand the potential improvements of maintaining SR with alternatives to AADs, such as ablation. METHODS: A discrete event simulation (DES) was developed predicting stroke and death in a population with AF using equations from AFFIRM. Individual patients were created and assigned unique attributes. Analyses were run over a ten year time horizon, wherein the AF burden (the time spent out of SR) was allowed to vary from 0 to 50%. Scenarios were evaluated wherein SR was attained with and without use of AADs. RESULTS: Under the assumption of perfect rhythm control, 17.1% of patients controlled with AADs were predicted to die, compared to only 12.8% of those controlled without AADs; 5.9% and 6.2% of these populations were predicted to have strokes, respectively. Strokes were higher in latter cohort because of improved survival. When the AF burden was increased to 25%, 19.5% and 14.6% were predicted to die, while 6.6% and 6.8% were predicted to have a stroke, respectively. A further increase of the AF burden to 50% resulted in predicted mortality of 22.1% and 16.7%, and stroke rates of 7.2% and 7.6%, respectively. CONCLUSIONS: Maintenance of SR improves survival in patients with AF, and without the use of AAD was predicted to yield a substantial incremental survival benefi t. These results indicate that techniques like ablation, which have been shown to be more effective than AAD for converting and maintaining SR would have important benefi ts in an AF population. (36% vs. 19%) . Furthermore, the lab was almost four times more likely to report that the INR was 1.0-1.49 -a range associated with a 13.5-fold increased risk of a thromboembolic event (18% vs. 5%). Overall, 29% of clinical decisions were projected to differ, depending on which measure was used. A majority (53%) of the predicted clinical differences occurred when the POC device reported a value within the target INR range. Based on epidemiologic evidence of risk as a function of the INR, we estimate that 67 thromboembolic events occurred over the 2.5 year period because of the discrepancy between the measures. CONCLUSIONS: There are clinically relevant differences between INR values reported by the Hemochron POC device and our clinical lab that were not detected by conventional methods. The Hemochron device biases INR measures towrd the target range throughout the INR scale. This bias prevents many necessary warfarin dosing changes because the clinician does not understand the patient's true risk level. Therefore, patients spend more time at INR levels strongly associated with an increased risk of a negative outcome.
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